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license (http://creativeto date, and development of new and advanced preclinical models that generate actionable knowledge
is desperately needed. This review reports on computer-based modeling and simulation approach as a
powerful tool in AD research. Statistical data-analysis techniques can identify associations between
certain data and phenotypes, such as diagnosis or disease progression. Other approaches integrate
domain expertise in a formalized mathematical way to understand how specific components of pa-
thology integrate into complex brain networks. Private-public partnerships focused on data sharing,
causal inference and pathway-based analysis, crowdsourcing, and mechanism-based quantitative sys-
tems modeling represent successful real-world modeling examples with substantial impact on CNS
diseases. Similar to other disease indications, successful real-world examples of advanced simulation
can generate actionable support of drug discovery and development in AD, illustrating the value that
can be generated for different stakeholders.
 2016 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Keywords: Brain disorders; Alzheimer’s dementia; Crowdsourcing; Private-public partnership; Quantitative systems pharma-cology; Regulatory1. Introduction
A major problem with Alzheimer’s disease (AD) drug
development is the lack of reliable models to predict clinical
efficacy during drug development. In stark contrast to the
99.6% failure rate of clinical trials, roughly 300 interventions
were reported to reduce pathology and/or improve behavior
in transgenic AD mouse models between 1995 and 2010 [1].
This illustrates the need for an alternative more human-
ized set of models that is better aligned with the clinical sit-
uation. Modeling and simulation might be a powerfulthor. Tel.: 11-609-218-2908.
agali.haas@cohenbio.org
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he Authors. Published by Elsevier Inc. on behalf of the Alzhe
commons.org/licenses/by-nc-nd/4.0/).alternative, especially when based on human clinical data
and with appropriate domain expertise. Existing “big data
analytics” cover a vast computational space ranging from
bottom-up dynamical systems modeling to top-down proba-
bilistic causal approaches. Avariety of methodologic frame-
works have been developed for modeling and analyzing
complex multivariate data that can be adapted to neurosci-
ence in general and AD in particular.
Despite extensive investment to identify biomarkers for
central nervous system (CNS) disorders, a large gap remains
between exploratory biomarkers and their validation and
integration into routine clinical practice. This gap exists in
part because conventional analysis methods focus on single
biomarker analysis, whereas most disease phenotypes arise
not from single genes and proteins but from a compleximer’s Association. This is an open access article under the CC BY-NC-ND
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approach for identifying disease markers adopts network
biology and pathway databases to infer differences between
populations of patients and the role of genes in disease in the
context of networks and pathways. The activity of these
entire networks and pathways can then be used as part of
the statistical analysis procedure—rather than, for example,
the expression levels of single genes—to characterize or
stratify patients into similar groups. The identification of
these pathways would also enable the identification of new
targets for disease intervention (either preventatively or
acutely).
Systems biology is an integrative approach that combines
theoretical modeling and direct experimentation. Theoret-
ical, or computational, models provide insights into experi-
mental observations, and experiments can provide data
needed for model creation or can confirm or refute model
findings. Many of our scientific breakthroughs and techno-
logic advances in other engineering industries rely on
models simulated on high-performance computers.
This revolution is now beginning to touch the fields of
neuroscience and brain research.
This article documents a few real-world examples of such
novel frameworks that can support these efforts in various
CNS indications. The report describes public-private part-
nerships (PPPs) with Clinical Path Institute (C-Path) as an
example, The Orion Bionetwork for Multiple Sclerosis, a
few examples of quantitative systems pharmacology (QSP)
for CNS, a crowdsourcing example of modeling in amyotro-
phic lateral sclerosis (ALS), and examples where regulatory
agencies used modeling and simulations. Although these ap-
proaches are certainly not perfect, they illustrate what can be
achieved in practical and actionable terms for addressing
well-defined questions and problems. Importantly, they
also identify possible pathways toward concrete solutions
for various stakeholders, including patient foundations, aca-
demics, regulatory agencies, and pharmaceutical companies.2. Public-private partnerships
There is a growing expansion in the number of AD PPPs
given the recognition that collaboration is essential [2].
The flagship PPPs, Alzheimer’s Disease Neuroimaging
Initiative (ADNI) and Parkinson’s Progressive Markers
Initiative (PPMI), are revolutionizing the understanding of
brain diseases, such as AD and Parkinson’s disease (PD),
by demonstrating that pathologic hallmarks originate in the
brain decades before the onset of symptoms. Despite these
significant advances in understanding the longitudinal pro-
gression of disease, disappointing results in clinical trials
that have evaluated biomarkers and potential disease modifi-
cation continue to pose challenges. Two critical success fac-
tors underlie why the ADNI and PPMI collaborations are so
impactful: (1) agreement on open sharing of patient-level
data to the broad research community and (2) agreement to
comply with consensus data standards for collection of alldata including patient diagnostic criteria and biomarker
standardized acquisition parameters. Although numerous
publications exist on methodologies for biomarker assay
standardization, there is no current mechanism in place for
sponsors conducting clinical trials to agree and conform to
consensus standards for data collection or open sharing of
patient data.3. The C-Path experience
C-Path was formed in 2004 to advance the goals set forth
in the Critical Path Initiative of the U.S. Food and Drug
Administration (FDA) [3]. One of C-Path’s many precompe-
titive consortia, the Coalition Against Major Diseases
(CAMD), was launched in September 2008 to develop
new technologies and methods to accelerate drug develop-
ment for AD and PD. CAMD convenes pharmaceutical in-
dustry, research and patient advocacy organizations,
regulatory and other government agencies, and academia
to achieve formal regulatory decisions endorsing outcome
measures, modeling and simulation, and biomarkers by
creating consensus data standards and enabling precompeti-
tive data sharing platforms [4].
Through partnership with Clinical Data Interchange Stan-
dards Consortium (CDISC), C-Path has successfully devel-
oped data standards for AD, PD, polycystic kidney
disease, tuberculosis, multiple sclerosis (MS) and most
recently, schizophrenia and traumatic train injury. The AD
CDISC standards represented the first such disease-specific
standards and a version 2.0 of the AD CDISC standards,
completed in early 2014, incorporates biomarkers and early
stages of the AD spectrum, specifically targeted at the stage
of mild cognitive impairment. These therapeutic area stan-
dards were developed with funding support from the FDA
and represent the preferred format by regulatory agencies
for new drug applications for expedited review. By 2017,
submission of new drug applications in CDISC standards
will likely be required by the FDA, suggesting that clinical
trials initiating at the present time should adopt these stan-
dards. Using these standards, CAMD remapped control-
arm patient-level data from AD clinical trials to populate
the CAMDAD database. This standardization facilitates an-
alyses of the data as a single-integrated source. Pooling data
in this fashion allow analysts to query all trials or subsets of
trials in the database without writing programming state-
ments for each new study. The database is available to qual-
ified researchers and currently consists of placebo clinical
data from 24 trials of about 6500 subjects in total [5]. The
CAMD AD database was fundamental to developing a
drug-disease-trial model for mild-to-moderate AD, which
became the first regulatory-endorsed quantitative clinical
trial simulation tool. This model describes the longitudinal
progression of the 11-item AD Assessment Scale Cognitive
sub-scale (ADAS-Cog) in AD patients from both natural his-
tory and randomized clinical trials, placebo effect, patient
dropouts, and different types of treatment effects [6]. With
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Agency, this tool is being adopted to optimize clinical trial
design for candidate therapeutics in AD [7].
4. Orion Bionetworks: A case study for computational
modeling of multiple sclerosis
MS is a leading cause of disability in young adults,
affecting.2.5 million individuals worldwide [8]. The path-
ogenic mechanisms that lead to the loss of immune homeo-
stasis, myelin and axonal injury, and progressive
neurological symptoms are incompletely understood
[9,10]. The clinical course of MS varies greatly, reflecting
the considerable complexity of pathogenesis and disease
expression. The current generation of disease-modifying
therapies generally treats the immune-modulatory compo-
nents of disease and is proven effective only for patients
with the relapse-remitting form of MS (RRMS). Diagnostic,
prognostic, and response biomarkers would aid in clinical
development of next-generation therapeutics as well as de-
livery of precision clinical care [11].
Orion Bionetworks, Inc., a Cambridge, MA–based
nonprofit research organization, was founded to bridge the
translational divide for brain disorders through the adoption
of a systems biology and modeling approach enabled
through a unique public-private alliance partnership model.
The Orion Bionetworks Flagship Program (launched in
2013) has successfully piloted the establishment of an MS
Bionetwork comprised of academic (Neuroscience Institute
of the Brigham and Women’s Hospital), advocacy (Acceler-
ated Cure Project for MS), computational (GNS Healthcare,
MetaCell, Thomson Reuters), informatics (Converge by De-
loitte, Rancho Biosciences, Exaptive), and online patient
community partners (PatientsLikeMe [PLM]) with funding
sponsorship provided by Janssen Pharmaceuticals and pub-
lic philanthropic donations. Deidentified data from three da-
tabases were curated and loaded into a cloud-based data
knowledge management system called TranSMART. The in-
tegrated repository includes .9000 subjects with MS and
related conditions.
The alliance developed a roadmap for joint execution
with specific scientific aims. Using a computational systems
modeling approach and our integrated database, we sought
to answer the following research questions:
 What is the natural course of MS disease progression
based on patient-derived and clinically derived data
sources?
 Does the current nosology of clinically isolated syn-
drome/RRMS/primary progressive MS/secondary pro-
gressive MS accurately reflect this pattern?
 Are there biomarkers of prognosis?
 Could we dissect the structure of the MS patient popu-
lation based on molecular pathways or other variables?
 How many patient subsets are there?
 How does this structure relate to disease course?
 How does this structure relate to treatment response? What are the most common comorbidities associated
with MS based on patient-reported experience, and
could we use the clinically derived data to model path-
ogenic mechanisms?
 What constitutes a “relapse” event and what are the
triggers?
 Could we build a systems model to understand the
pathophysiology of neurodegeneration in MS?
To date, the alliance has generated three models (dis-
cussed below) based on the data repository using different
algorithmic approaches.
4.1. Phenotypic prognostic model
To develop our phenotypic prognostic model, data from a
database amassed by PLM on .35,000 patients with MS
was used. The database comprised two major sets of patient
self-reported outcomes: (1) Multiple Sclerosis Rating Scale
(MSRS) and (2) General Symptoms Scale as well as key de-
mographic variables on each patient (e.g., age, gender, diag-
nosis, location). The PLM online platform uses a structured
data collection process that largely mirrors data collected
from a clinical research environment [12]. Key variables
collected in the MSRS included walking, upper limb func-
tion, vision, speech, swallowing, thinking/memory/cogni-
tion, and sensation/burning/pain. Key outcomes collected
in the General Symptoms Scale included anxious mood,
depressed mood, fatigue, insomnia, pain, bladder problems,
bowel problems, brain fog, emotional lability, somnolence,
mood swings, sexual dysfunction, and stiffness/spasticity.
Summary statistics were generated for all key outcomes
(e.g., symptom severity over time). We also generated a
linear stepwise-regression model to project the MS course
for an individual patient based on their history of symptoms.
Complete results have been submitted for publication.
4.2. Molecular prognostic models
To develop our molecular prognostic models, data from a
clinical study database calledCLIMB [13] were used to build
two separate models. GNS Healthcare developed a data-
driven model using Bayesian causal inference modeling
[14], whereas Thomson Reuters used a pathway-based anal-
ysis approach that incorporated “priors” from the literature
[15]. It has been shown in a number of studies that approaches
based on utilization of prior knowledge perform better (e.g.,
accuracy, reproducibility, and robustness of the models) than
purely data-driven approaches for such applications as
biomarker identification, patient stratification [15–20], and
clustering analysis for subgroup identification [21]. A
network-based analysis approach was tested for MS based
on genome-wide association studies (GWAS) data [22].
These molecular models were generated from the CLIMB
database, which includes.2000 RRMS patient’s longitudi-
nal (up to 5 years) data including demographic, clinical, mag-
netic resonance imaging (MRI), and genetic (GWAS and
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to model disease progression (time to relapse or reduced
functioning on Kurtzkee Functional Scale) as a function of
clinical and/or molecular variables. Complete results have
been submitted for publication elsewhere.
The alliance quickly recognized the need to develop new
informatics and visualization tools to work with these large
data sets and models.4.3. Bioinformatics infrastructure
Orion Bionetworks has funded the development and
deployment of several open-source and proprietary data
management and modeling and visualization tools. Orion
has an established data management system called TranS-
MART that houses all the deidentified clinical and pheno-
typic data provided to the alliance [23]. This cloud-based
infrastructure is secure and password-protected for use by
the alliance partners. TranSMART is a knowledge manage-
ment platform that enables scientists to develop and refine
research hypotheses by investigating correlations between
genetic and phenotypic data, and assessing their analytical
results in the context of published literature and other
work [24]. ItsWeb interface, backed by a powerful R engine,
provides a standardized process for data analysis and visual-
ization. With our alliance partner, Exaptive Inc., we have
developed plug-in visualization tools that support hypothesis
testing and simulations.
In summary, by using data sets of convenience, we were
able to build two powerful in silico models that can be used
to run simulations of different conditions to help us interro-
gate complex systems pathways leading to different disease
outcomes. This modeling exercise allowed us to identify
critical gaps to build more robust and predictive models
for MS and other brain disorders.5. Prediction of clinical outcomes with quantitative
systems pharmacology in schizophrenia and AD
QSP is an advanced mechanism-based simulation plat-
form of biophysically realistic humanized neuronal circuits,
consisting of different types of neurons and using Hodgkin–
Huxley equations to calculate the actual time-dependent
membrane potential changes [25]. Voltage-gated ion chan-
nels can be modulated by various neurotransmitters, such
as dopamine, serotonin, norepinephrine, and acetylcholine,
and human pathology can be introduced using clinical imag-
ing and postmortem data. The platform’s architecture is
based on the human brain neuroanatomy and neurophysi-
ology and includes a number of cortico-striatal-thalamo-
cortical loops with the appropriate different cell types.
Localization of membrane receptors and ion channels and
their intracellular regulation is derived from literature and
reflects the domain expertise collected in the neuroscience
community. Key biological coupling parameters between
receptor activation and subsequent change in voltage-gatedion channels are calibrated using a correlation between
model outcome and actual historical clinical outcomes for
a large number of pharmacological interventions, such as
ADAS-Cog changes over timewith different doses of acetyl-
cholinesterases and 5-H6 antagonist SB742457 [26].
This section documents a number of cases where the QSP
platform has been used successfully in CNS disorders.
The computer model blindly predicted, purely based on the
preclinical pharmacology, that PF-04995274, a selective 5-
HT4 partial agonist with beneficial improvement in traditional
preclinical animal models, would actually worsen cognitive
outcomes in a phase I scopolamine study with human volun-
teers. This unexpected clinical prediction was indeed
confirmed subsequently [27], and the clinical development
project was halted, despite the fact that back-up compounds
withdifferent pharmacologyshowedagreater effect on thepre-
dictive cognitive outcome and could have had a higher chance
of success in clinical trials for AD. Conversely, the QSP plat-
form identified a different AD patient population likely to
respond successfully to the selected clinical candidate [27].
In this case, the translational gap between the animal and
computer models in predicting the clinical response was
largely driven by the differences in serotonin dynamics
and interaction of the candidate drug with the human targets
versus the rodent receptors. Because of the in silico nature
and the calibration with human imaging studies, the human-
ized platform captured the serotonin dynamics of the human
brain better than rodent models.
The predictive power of QSP in schizophrenia has been
demonstrated with the phase II predictions of JNJ37822681,
a low-affinity selective D2R antagonist and ocaperidone, a
high-affinity multi-target D2 antagonist [28]. In this study,
the modelers were kept blinded to the actual clinical
outcome and the QSP model correctly predicted a high–mo-
tor side-effect liability that was not observed in preclinical
animal models and that led to the demise of the clinical
development project. In contrast, the model was unable to
predict the relative high placebo effect in the ocaperidone
trial, but correctly and quantitatively predicted the relative
clinical improvement (i.e. the difference) of ocaperidone
compared with placebo.
A third example refers to the new 5-HT2C agonist vabica-
serin as a stand-alone in schizophrenia [29]. This new target
was introduced in the neuronal circuitry based on preclinical
animal neurophysiology, and the dose-dependent outcome
of an agonist at this receptor as a stand-alone therapy in
schizophrenia patients was simulated. Comparison with
the actual phase II outcomes showed that the model approx-
imately predicted the effect size of the drug on the total Pos-
itive and Negative Syndrome Scale score, which was much
lower than reference antipsychotics and therefore was insuf-
ficient to warrant a full clinical development program. Note
that the preclinical animal models that usually give a binary
response (yes/no) resulted in an equipotent response
compared to reference antipsychotics, suggesting that this
target would be a valuable development project.
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was used to identify the biological rationale for responders to
the antipsychotic iloperidone [30] in schizophrenia patients.
In this study, the drug pharmacology was kept constant,
whereas the biological coupling parameters were allowed to
fluctuate around their optimal values; optimization of iloper-
idone response in this model identified the coupling between
D4R andAMPA on pyramidal cells as the major driver, in line
with one reported genotype in amore traditional pharmacoge-
nomics analysis [31]. This approach allows in principle to
identify the pathways and circuits and therefore the single-
nucleotide polymorphism candidates thatwould drive clinical
response to a specific therapeutic intervention.
In another example with implications for polypharmacy
treatment in real-life, the nonlinear pharmacodynamic inter-
actions between acetylcholinesterases, memantine, and
smoking in combination with specific antipsychotics was
simulated in cognitive impairment in schizophrenia [32].
Although the study identified a few cases of positive synergy,
most of the results suggested that pharmacodynamic
drug-drug interactions had a negative impact on cognition.
Interestingly, this study generated hypotheses as to why re-Fig. 1. Possible virtual patient strategy by implementing quantitative systems pha
Pharmacokinetic (PK) modeling (blue lines) based on phase I studies can be used t
interaction with co-medications can be simulated based on the known affinity of t
lines) based on PET tracer displacement studies or noninvasive biomarkers such as B
engagement. The effect of co-medications and genotypes on a pharmacodynamic (
macology of CNS-active co-medications and the implementation of common gen
circadian rhythm of key targets can be incorporated into the QSP platform to de
sion/exclusion criteria, and genotype stratification. Finally, a virtual patient trial w
genotypic, and biological variability can be combined with PK variability to betteported clinical results with these compoundswere so variable,
ranging from a negative effect to a positive synergy.
These examples demonstrate that integrating QSP ap-
proaches at an early stage in drug discovery can help phar-
maceutical companies identify the optimal clinical
candidate and validate relevant targets. Alternatively, as
demonstrated in the example of the 5-HT4 agonist, the
approach can identify stronger and better clinical candidates
in discovery research. By using virtual patients, such an
approach can provide guidance for personalized and rational
therapeutic polypharmacy. Fig. 1 shows a possible strategy
to implement this form of QSP in a clinical development
program.6. Using crowdsourcing to bridge between big data tools
and neurodegenerative diseases
ALS is a neurodegenerative disease that specifically at-
tacks motor neurons, leading to progressive paralysis and
death, typically within 3–5 years. One in 1000 people will
die of ALS [33], and it has no effective treatment. The
heterogeneity of ALS manifestation—similar to allrmacology (QSP) in a clinical development program for a novel drug target.
o derive a model for the dose and time dependency of plasma levels. PK-PK
he drugs for metabolizing enzymes and transporters. QSP simulation (black
OLD fMRI or phEEG can be used to obtain an estimate of anticipated target
PD) readout can be derived in the mechanism-based platform from the phar-
otypes. Different disease states can be simulated, and available data on the
termine the optimal conditions of dose selection, patient population, inclu-
here individual “subjects” are sampled from probability distributions around
r estimate the number of patients needed to identify a clinical robust signal.
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the planning and interpretation of clinical trials for ALS treat-
ments, leading to large, expensive clinical trials and even
worse, the potential failure of an effective drug that will not
reach patients solely due to the variability of patients in the
trial. Indeed, recent failures in large clinical trials have left
the drug industry and the patient population looking for
new approaches and solutions.
Prize4Life, a nonprofit dedicated to the acceleration of
treatments and a cure for ALS, was determined to address
this need and remove the barriers for the development of
ALS treatments. To effectively address this problem, two
important tools are needed:
(1) A large data set of clinical, longitudinal, and patient
information, with as diverse data sets as possible, to
provide a comprehensive overview of the patient dis-
ease state,
(2) New computational approaches obtainable through
crowdsourcing.
Large sample data sets are critical for identifying statisti-
cally significant and biologically relevant variables, particu-
larly for diseases resulting from the complex interplay of
genetic and environmental factors. To reach such large sample
data sets, pooled clinical trial data sets have proven to be an
invaluable resource for researchers seeking to unravel other
complex neurodegenerative diseases [4,6,34,35]. With that
in mind, Prize4Life collaborated with the Neurological
Clinical Research Institute at Massachusetts General
Hospital to create the Pooled Resource Open-Access ALS
Clinical Trials (PRO-ACT, www.ALSdatabase.org) platform
with funding from the ALS Therapy Alliance and in partner-
ship with the Northeast ALS Consortium. The vision of the
PRO-ACT project was to accelerate and enhance translational
ALS research by designing and building a data set that would
contain themerged data fromasmany completedALS clinical
trials as possible. Containing.8600 patients [36], PRO-ACT
was launched as an open access platform for researchers in
December 2012. Since then, it has been used by over 1000 re-
searchers.
One effective way to foster the development of effective
and diverse computational tools, and facilitate an unbiased
assessment of their performance, is through crowdsourcing
[37]. Crowdsourcing also allows for reaching out to new dis-
ciplines previously not engaged in ALS research.
To address the question of the variability in the progression
of ALS, a subset of the PRO-ACT data was used before its
public launch for an international crowdsourcing initiative,
The DREAM-Phil Bowen ALS Prediction Prize4Life. The
challenge asked solvers to predict the rate of progression of
ALS for individual patients over the course of a year, using
only 3 months of data. Algorithms were evaluated in a statis-
tically rigorous blinded assessment. The prize ($50,000) was
to be awarded for the most accurate methods to predict
ALS progression. The challenge was administered through a
collaboration between the Dialogue for Reverse EngineeringAssessments and Methods (DREAM) initiative and Prize4-
Life using the InnoCentive Platform.
The challenge drew 1073 solvers from 63 countries and
resulted in the submission of 37 unique algorithms from
which two winning entries were identified, with one team
coming from an analytic marketing company, Sentrana,
Washington DC, and another team from Stanford University.
In a post-challenge survey, 80% of the solvers who re-
sponded indicated they had minimal knowledge regarding
ALS before participation.
The best-performing algorithms predicted disease pro-
gression better than both a baseline model and clinicians us-
ing the same data. Clinical trial modeling indicates that
using the algorithms should enable a substantial reduction
of .20% in the population size of a clinical trial required
to demonstrate a drug effect, which translates to reduction
of millions of dollars in the costs of all clinical trials using
the data [38]. The algorithms are now in use or under consid-
eration by several pharmaceutical companies and re-
searchers.
Finally, the challenge was able to also offer new insights
into factors predicting ALS progression. The prediction al-
gorithms not only corroborated several previously identified
predictive features, including uric acid, age, site of onset,
and time from onset, the algorithms also uncovered several
clinical measurements formerly unknown to be predictive
of disease progression, including creatinine, creatine kinase,
pulse, phosphorus, and blood pressure. These readily ob-
tained measures hold promise to further our understanding
and, one day, treatment of ALS.
Overall, this example demonstrates the potential of using
pooled clinical trial data and crowdsourcing initiatives to
develop newmodels and tools for better research and develop-
ment in neurodegenerative diseases.More broadly, it suggests
that improved access to better, larger, and more diverse data
sets of patient data holds a great promise for improving clin-
ical development and clinical practice beyond its current state.7. Other examples of modeling influencing regulatory
decisions
There are a few examples where modeling and simulation
have helped influence regulatory agencies to approve a drug
under slightly different conditions without the need for addi-
tional clinical trials. In post-herpetic neuralgia, regulatory
approval for specific doses of gabapentin was granted based
on sophisticated exposure-response modeling using five clin-
ical trials with different doses [39,40] without the need to
conduct another clinical trial. The approved label mentioned
explicitly that “pharmacokinetic/pharmacodynamic (PK/
PD) modeling provided confirmatory evidence of efficacy
across all doses.” The anti-epileptic oxcarbazepine (Trileptal)
was approved as monotherapy in children, based on advanced
PK/PD modeling [41] and subsequently confirmed in a
clinical trial [42].
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used for simulating the impact of human recombinant para-
thyroid hormone [43] with regard to alternative dosing reg-
imens. This suggests that regulatory agencies are becoming
increasingly interested in advanced multiscale modeling and
simulation beyond the more traditional PK/PD modeling.
8. Discussion
This position paper discusses some examples and real-
world tests of models and simulations for generating action-
able knowledge from many databases that are currently
being collected and the domain expertise that has been
generated in the neuroscience community. For AD, we inter-
pret “actionable” as knowledge that can be used to actively
support drug discovery programs for therapeutic interven-
tions (in terms of target validation and identification of the
optimal modulation strategy for the selected target), to iden-
tify possible responder populations for specific targets, and
to validate clinical readouts that can demonstrate relevant
changes in disease progression.
The examples in this report range from sharing data ini-
tiatives in precompetitive consortia such as C-Path and
ADNI over crowdsourcing to better define the historical dis-
ease progression in ALS and identifying novel pathways in
MS to mechanism-based predictive modeling of virtual hu-
man patients that could inform the selection of clinical can-
didates for drug development, improve clinical trial design,
or guide rational polypharmacy in real-world situations.
The examples also illustrate the wide variety of relevant
stakeholders, ranging from preclinical and clinical re-
searchers, regulatory agencies, and pharmaceutical com-
panies. Obviously in all these projects, patients remain the
most important stakeholders and provide the most important
information for the development and validation of the
different analysis techniques. The engagement of regulators
enables decisions that have implications across multiple tar-
gets independent of the sponsor and the precise mechanism
of action of drug candidates. Ultimately, the purpose of pre-
dictivemodeling in this disease area is to get the right drug to
the right patients in the shortest amount of time.
It is also important to realize that different scientific ques-
tions need to be addressed with different levels of detail in
various models. First and foremost, data sharing in a stan-
dardized format is an essential requirement for generating
actionable knowledge. This applies both to data from real-
life situations and to data from clinical trials. Initiatives
such as C-Path and the Innovative Medicines Initiative are
making progress on this issue.
For some qualitative relationships (e.g., the factors
driving clinical progression), deep analytical approaches
based on advanced statistical approaches are probably suffi-
cient, as illustrated in the example of ALS and Orion Bio-
Networks. These approaches can also address more
complex quantitative issues such as a better estimation of
the progression of placebo trajectory.For more predictive and quantitative questions that are
relevant to actual drug discovery and development (i.e., in
what direction and how much do we need to therapeutically
affect one or more biological processes to have a substantial
impact on the clinical phenotype in a specific patient popu-
lation), formalized integration of extensive neurobiological
domain expertise seems to be a solution to define better
the causality between different biological processes as illus-
trated by the QSP.
This last example also illustrates the predictive nature,
that is, the ability to estimate the clinical trial outcome of
a new intervention, purely based on preclinical information.
Going from purely exploratory analyses to approaches that
are more predictive in nature is absolutely essential to sup-
port the development of new and better therapeutic interven-
tions. By combining data and advanced modeling algorithms
with formalized domain expertise of neurophysiologists, cli-
nicians, imagers, and neuropharmacologists, this approach
has the capability of being a game changer in the quest for
new and effective drugs for AD.
In summary, this article shows a number of real-world
examples of predictive modeling in CNS diseases in general
and in AD in particular. Impact for this approach is evident
for all phases of drug development. The different examples,
using various analytical approaches, illustrate the impact
and level of detail that can be achieved for the different
stakeholders. These approaches could be a good starting
point to expand the toolbox of the next-generation analysis
techniques that will help bring the right drug to the right
patient.RESEARCH IN CONTEXT
1. Systematic review: We searched for various real-
world examples for predictive modeling for CNS
disorders that had shown actual real benefit for
helping drug discovery and development.
2. Interpretation: We described private-public partner-
ships focused on data sharing, causal inference, and
pathway-based analysis in multiple sclerosis,
crowdsourcing in ALS and mechanism-based quan-
titative systems modeling in Alzheimer’s disease
with predictive value and potential impact on R&D.
In at least one case, a quantitative and unexpected
prediction was confirmed in a subsequent clinical
trial.
3. Future directions: We intend to update the list on a
regular basis to demonstrate that such in silico ap-
proaches can have a valuable impact on CNS
research and development programs.
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